Abstract
Although remarkable therapeutic advances in the treatment of cardiometabolic disorders have been made with current therapeutic options, cardiovascular disease (CVD) is still a leading cause of mortality and morbidity in the Western world. Therefore, to develop a novel therapeutic strategy is needed for the prevention of cardiovascular disease (CVD) in high-risk patients for atherosclerosis. Recently, we, along with others, have shown that pigment epithelium-derived factor (PEDF), a glycoprotein with potent neuronal differentiating activity, exerts anti-oxidative and anti-inflammatory properties in vascular wall cells, leukocytes and platelets. In addition, PEDF not only suppresses neointimal hyperplasia after balloon angioplasty, but also blocks occlusive thrombus formation in a rat arterial thrombosis model. These observations suggest that substitution of PEDF may be a novel therapeutic strategy for atherosclerosis. This article summarizes the pathophysiological role of PEDF in atherosclerosis and its potential therapeutic implication in this devastating disorder. We also discuss here the kinetics and regulation of PEDF in cardiometabolic disorders in humans.
Keywords: Atherosclerosis, cardiometabolic disease, oxidative stress, PEDF
Current Pharmaceutical Design
Title: Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
Volume: 15 Issue: 9
Author(s): Sho-ichi Yamagishi, Takanori Matsui and Kazuo Nakamura
Affiliation:
Keywords: Atherosclerosis, cardiometabolic disease, oxidative stress, PEDF
Abstract: Although remarkable therapeutic advances in the treatment of cardiometabolic disorders have been made with current therapeutic options, cardiovascular disease (CVD) is still a leading cause of mortality and morbidity in the Western world. Therefore, to develop a novel therapeutic strategy is needed for the prevention of cardiovascular disease (CVD) in high-risk patients for atherosclerosis. Recently, we, along with others, have shown that pigment epithelium-derived factor (PEDF), a glycoprotein with potent neuronal differentiating activity, exerts anti-oxidative and anti-inflammatory properties in vascular wall cells, leukocytes and platelets. In addition, PEDF not only suppresses neointimal hyperplasia after balloon angioplasty, but also blocks occlusive thrombus formation in a rat arterial thrombosis model. These observations suggest that substitution of PEDF may be a novel therapeutic strategy for atherosclerosis. This article summarizes the pathophysiological role of PEDF in atherosclerosis and its potential therapeutic implication in this devastating disorder. We also discuss here the kinetics and regulation of PEDF in cardiometabolic disorders in humans.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Matsui Takanori and Nakamura Kazuo, Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787581940
DOI https://dx.doi.org/10.2174/138161209787581940 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytotoxicity and Anti-inflammatory Activity of Flavonoid Derivatives Targeting NF-kappaB
Recent Patents on Inflammation & Allergy Drug Discovery Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke
Current Pharmaceutical Design Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Role of Reactive Oxygen Species in Tumor Necrosis Factor-alpha Induced Endothelial Dysfunction
Current Hypertension Reviews Condensed and Hydrolysable Tannins as Antioxidants Influencing the Health
Mini-Reviews in Medicinal Chemistry Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy
CNS & Neurological Disorders - Drug Targets Urea Derivatives as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
Current Drug Targets Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Association Between Neutrophil to Lymphocyte Ratio and Malignant Brain Edema in Patients With Large Hemispheric Infarction
Current Neurovascular Research Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect
Current Neuropharmacology